Search results
Found 18567 matches for
MSc Taught Course in Clinical and Therapeutic Neuroscience
The one-year, full-time taught MSc is delivered by pre-clinical and clinical research teams based in the Department of Psychiatry, in Oxford University centres within the neuroscience community, and in the NIHR Oxford Cognitive Health Clinical Research Facility.
Tereza presents her work on treating depression during COVID-19 through online behavioural activation
DPhil student Tereza recently attended the Asian Cognitive Behavioural Therapy Association to present her work on treating depression during COVID-19 through online behavioural activation. The meeting was an excellent opportunity to learn about the global applications of CBT and to hear from renowned experts such as Dr Judith Beck.
PERL at the Oxford Neuroscience Experience
The Oxford Neuroscience Experience is an annual public engagement event where Year 12 pupils are invited to gain an insight into what neuroscience at Oxford looks like. The experience aims to expose the pupils to some of the fundamental questions addressed by neuroscience research.
Photovoice
A series of videos discussing why we decided to use photovoice and what it involves
Co-PACT Team
Co-Pact involves a number of people from different organisations, click 'read more' to find out who is involved!
Selected PPiP2 study documents for researchers
Click on the desired document to start the download. If you cannot find a document you need please email the central research team at ppip@psych.ox.ac.uk
About Us
SINAPPS stands for Study of Immunology in Antibody Positive Psychosis. We are a research group formed of collaborating Universities in the UK, investigating the role of autoimmune antibodies as a cause of psychosis.
Studies
Below is a list of SINAPPS Group studies both current and closed
Get Involved
We are offering tests for antibodies in people experiencing psychosis symptoms through the Prevalence of Pathogenic Antibodies in Psychosis 2 study (PPiP2)
Advice for Clinicians
The findings from previous studies suggest that approximately 5-10% of patients presenting to NHS Early Intervention in Psychosis services are positive for autoantibodies against neuronal targets (Lennox et al, 2016, Zandi et al, 2011).
Resources and Glossary
Here you will find a list of resource links and and a glossary related to our research.
Study of Immunology in Antibody Positive Psychosis 1 (SINAPPS1) 2015 - 2017
SINAPPS1 was as open label study of the feasibility of plasmapheresis or intravenous immunoglobulin, combined with corticosteroids, in patients with acute psychosis and anti-neuronal membrane auto-antibodies. The aim of SINAPPS1 was to investigate delivering immunotherapy to this patient group in general hospital settings.
SINAPPS2 Trial
SINAPPS2 is a phase II ongoing clinical trial aiming to test the efficacy and safety of immunotherapy (intravenous immunoglobulin combined with rituximab) vs placebo treatment in people with acute symptoms of psychosis and anti-neuronal membrane antibodies.
SINAPPS2 Trial Procedures
Please note that the following information, while true and detailed, is not exhaustive of the study procedures. A full Participant Information Sheet will be given to potential trial participants and a researcher and neurologist will be available to discuss the details of the trial before an offer of participation.